替罗非班对急诊经皮冠状动脉介入术患者的疗效

目的:探讨替罗非班治疗急性ST段抬高型心肌梗死(STEMI)急诊经皮冠状动脉介入术(PCI)患者的有效性及安全性。方法:对阿司匹林加氯吡格雷常规治疗组(对照组)50例和加用替罗非班三联抗血小板治疗组(观察组)50例的临床资料进行回顾分析。结果:PCI术后30 d,观察组出现的主要不良心血管事件,包括心源性死亡、非致死性心肌再梗死、靶血管再次血运重建、严重心绞痛的发生率为4.0%,低于对照组的18.0%(P0.05);PCI术后48 h及30 d,2组轻度出血及血小板减少并发症的发生率差异均无统计学意义(P0.05),2组均未发生严重出血并发症。结论:STEMI患者行急诊PCI术中及术后48 h联合应用替罗非班治疗能进一步减少术后30 d主要不良心血管事件,且安全性良好。

Effect of tirofiban on patients undergoing primary percutaneous coronary intervention

Objective：To investigate the efficacy and safety of tirofiban in the treatment of patients receiving primary percutaneous coronary intervention（PCI） for acute ST-segment elevation myocardial infarction （STEMI）. Methods：The clinical data of 100 patients with acute STEMI were analyzed retrospectively. Fifty of them （ control group） received dual antiplatelet therapy （DAPT） （ aspirin and clopidogrel） before and after primary PCI, and the other fifty （experimental group） received trigeminy antiplatelet therapy （aspirin, clopidogrel and tirofiban） till 48 hours after primary PCI. Results： At 30 days, the incidence of major adverse cardiovascular events includingcardiac death, non-fetal M1, target vessel revascularization and severe unstable angina in the experimental group was 4.0%, which was significantly lower than the 18.0% in the control group（ P 〈 0.05 ）. From 48 hours up to 30 days, the incidence of minor bleeding and thrombocytopenia had no significant difference between the two groups（ P 〉 0.05 ）. No major bleeding occurred in either group. Conclusions：Adding tirofiban to DAPT could safely decrease the incidence of 30 day MACE in patients with STEMI undergoing primary PCL